Cinven today announces that it has successfully completed the sale of 3 million shares, representing approx. 8% of share capital in Medpace Holdings Inc (‘Medpace’ or ‘the Group’), the leading global contract research organisation (CRO), at US$41.80 per share.

Following the offering, Cinven’s remaining stake in Medpace represents around 29% of the Group’s outstanding basic shares.  The transaction is expected to close on or around 14 June 2018.